LeukoScan Launched In First Markets
Immunomedics has launched LeukoScan, its radiolabeled monoclonalantibody fragment for the detection of infectious disease, in Germany and Austria. Launches in the UK and Ireland were also scheduled for just after the Marketletter went to press (April 24). These are the first introductions for LeukoScan, which is Immunomedics' second commercial product after CEA-Scan for colorectal cancer imaging.
The approved indication for LeukoScan is the detection and diagnosis of osteomyelitis involving long bones, particularly in diabetic patients with foot ulcers. Future indications could include acute atypical appendicitis. Meanwhile, the application for approval of LeukoScan is under review in the USA.
LeukoScan will be distributed by Mallinckrodt Medical, which also partners Immunomedics for the sale of its CEA-Scan product in Europe and the USA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze